ClinicalTrials.gg
CompletedNCT04995484Updated Jan 13, 2025Results posted

A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

A Phase 1 interventional study of Belzutifan in Moderate Hepatic Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 80 mg dose of belzutifan in participants with moderate hepatic impairment.

02

Conditions studied

  • Moderate Hepatic Impairment
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Participants:

  • Is in good health.
  • Has a (BMI) 18.0-40.0 kg/m\^2.

For Participants With Normal Hepatic Function:

Male Participants -Must have been vasectomized or surgically sterilized for at least 4 months or more prior to study intervention administration and agree to the following during the intervention period and for at least 5 days after administration of study intervention, be abstinent from heterosexual intercourse as their preferred and usual lifestyle or must agree to use a male condom plus partner use of an additional method when having penile-vaginal intercourse with a woman of (WOCBP) who is not currently pregnant.

Female Participants

-Is a woman of non-childbearing potential (WONCBP).

For Participants With Moderate Hepatic Impairment

  • Has a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 30 days from administration of study intervention due to deterioration in hepatic function) hepatic impairment.
  • Has a score on the scale of B (a score of 7-9 on Child-Pugh Score)

Male Participants -Have been vasectomized or surgically sterilized for at least 4 months or more prior to study intervention administration and agree to the following during the intervention period and for at least 5 days after administration of study intervention, be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant.

Female Participants

  • Must be a WONCBP.

Exclusion criteria

Exclusion Criteria:

All Participants:

  • Is a heavy smoker or heavy user of nicotine-containing products (>20 cigarettes or equivalent/day).
  • Consumes greater than 3 glasses of alcoholic beverages or equivalent per day.
  • Consumes excessive amounts, defined as greater than 6 servings of caffeinated beverages per day.
  • Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within the last 2 years.
  • Presents any concern by the investigator regarding safe participation in the study.

For Participants with Normal Hepatic Function

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder of the last 5 years.
  • Has a history of cancer ().
  • Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
  • Is positive for surface antigen (HBsAg), antibodies, or (HIV).
  • Had major surgery, donated or lost 1 unit of blood within the last 4 weeks.
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs (with the exception of prescription drugs that are approved by the investigator and Sponsor) or herbal remedies for the prohibited period of time.
  • Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
  • Has participated in another study within 4 weeks prior to study intervention administration.

For Participants With Moderate Hepatic Impairment

  • Is mentally or legally incapacitated, has significant emotional problems or has a history of clinically significant psychiatric disorder in the last 5 years.
  • Has a history of cancer (malignancy).
  • Has a history of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
  • Has fluctuating or rapidly deteriorating hepatic function.
  • Has a history of liver or other solid organ transplantation.
  • Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting.
  • Has encephalopathy Grade 3 or worse within 28 days before administration of study intervention.
  • Is positive for HIV.
  • Has had major surgery, donated or lost 1 unit of blood within the last 4 weeks.
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs (with the exception of prescription drugs that are approved by the investigator and Sponsor) or herbal remedies for the prohibited period of time.
  • Has received any nonlive vaccine starting from 14 days prior to study intervention or is scheduled to receive any nonlive vaccine through 30 days following study intervention. Exception: COVID-19 vaccine may be administered.
  • Has participated in another investigational study within 4 weeks prior to study intervention administration.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Participants with moderate hepatic impairment will receive a single oral 80 mg dose of belzutifan on Day 1.

    Drug: Belzutifan

  • Experimental
    Healthy

    Participants with normal hepatic function will receive a single oral 80 mg dose of belzutifan on Day 1.

    Drug: Belzutifan

Interventions

  • Two 40 mg tablets given as a single oral 80 mg dose.

    Also known as: MK-6482, PT2977, WELIREG

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan

    AUC0-Inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-Inf of belzutifan.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose

  2. Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan

    AUC0-24hrs was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0 to 24 hours of belzutifan.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24 hours postdose

  3. Maximum Plasma Concentration (Cmax) of Belzutifan

    Cmax was defined as the peak level belzutifan reaches in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose

  4. Time to Maximum Plasma Concentration (Tmax) of Belzutifan

    Tmax was defined as the time it took belzutifan to reach its peak level in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine the Tmax of belzutifan.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose

  5. Apparent Terminal Half-life (t1/2) of Belzutifan

    Apparent terminal half-life (t1/2) was defined as the time needed to reduce the level of belzutifan in the blood by one-half (1/2). Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal half-life (t1/2) of belzutifan.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is reported.

    Time frame: Up to 15 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued the study due to an AE is reported.

    Time frame: Up to 15 days

07

Results

Posted Jan 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneModerate Hepatic ImpairmentHealthy
Started98
Completed98
Not completed00

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan

AUC0-Inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-Inf of belzutifan.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan
ng*hr/mLModerate Hepatic ImpairmentHealthy
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of Belzutifan22500 ± 80.314800 ± 35.1
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy · Geometric mean ratio: 1.52 · 90% CI 0.95 to 2.43Moderate Hepatic Impairment/Healthy
PrimaryArea Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan

AUC0-24hrs was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0 to 24 hours of belzutifan.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan
ng*hr/mLModerate Hepatic ImpairmentHealthy
Area Under the Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24hrs) of Belzutifan10500 ± 34.59650 ± 28.8
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy · Geometric mean ratio: 1.09 · 90% CI 0.84 to 1.42Moderate Hepatic Impairment/Healthy
PrimaryMaximum Plasma Concentration (Cmax) of Belzutifan

Cmax was defined as the peak level belzutifan reaches in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Belzutifan
ng/mLModerate Hepatic ImpairmentHealthy
Maximum Plasma Concentration (Cmax) of Belzutifan852 ± 28.7870 ± 31.4
Statistical analysis
  • Moderate Hepatic Impairment vs Healthy · Geometric mean ratio: 0.98 · 90% CI 0.76 to 1.26Moderate Hepatic Impairment/Healthy
PrimaryTime to Maximum Plasma Concentration (Tmax) of Belzutifan

Tmax was defined as the time it took belzutifan to reach its peak level in the blood. Blood samples collected predose and at multiple timepoints postdose were used to determine the Tmax of belzutifan.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Reported as:
Median · hr
Time to Maximum Plasma Concentration (Tmax) of Belzutifan
hrModerate Hepatic ImpairmentHealthy
Time to Maximum Plasma Concentration (Tmax) of Belzutifan2.00 (0.50 to 3.00)2.00 (1.00 to 3.00)
PrimaryApparent Terminal Half-life (t1/2) of Belzutifan

Apparent terminal half-life (t1/2) was defined as the time needed to reduce the level of belzutifan in the blood by one-half (1/2). Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal half-life (t1/2) of belzutifan.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96, and 120 hours postdose
Reported as:
Geometric mean · hr
Apparent Terminal Half-life (t1/2) of Belzutifan
hrModerate Hepatic ImpairmentHealthy
Apparent Terminal Half-life (t1/2) of Belzutifan23.5 ± 70.515.4 ± 16.4
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE is reported.

Time frame:
Up to 15 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience an Adverse Event (AE)
ParticipantsModerate Hepatic ImpairmentHealthy
Number of Participants Who Experience an Adverse Event (AE)11
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued the study due to an AE is reported.

Time frame:
Up to 15 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an AE
ParticipantsModerate Hepatic ImpairmentHealthy
Number of Participants Who Discontinue Study Treatment Due to an AE00

Adverse events

Collected over Up to 15 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Moderate Hepatic Impairment0/9 (0%)0/9 (0%)1/9 (11.1%)
Healthy Matched Control0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventModerate Hepatic ImpairmentHealthy Matched Control
HeadacheNervous system disorders0/91/8
DyspepsiaGastrointestinal disorders1/90/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Moderate Hepatic ImpairmentHealthyTotal
Mean60.7 ± 2.6961.4 ± 5.6361.0 ± 4.20
Sex: Female, Male
Sex: Female, Male(Participants)Moderate Hepatic ImpairmentHealthyTotal
Female8816
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthyTotal
Hispanic or Latino235
Not Hispanic or Latino7512
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Moderate Hepatic ImpairmentHealthyTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White9615
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Orlando Clinical Research Center ( Site 0001)
    Orlando, Florida 32809, United States
  • The Texas Liver Institute ( Site 0002)
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Dec 2023, 18 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 9, 2021
StartActual
Jun 24, 2022
Primary completionActual
Dec 25, 2023
CompletionActual
Jan 3, 2024
Results first posted
Jan 13, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04995484
Responsible party
Sponsor
First posted
Aug 9, 2021
Start date
Jun 24, 2022
Primary completion
Dec 25, 2023
Completion
Jan 3, 2024
Results posted
Jan 13, 2025
Last update
Jan 13, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzutifan

Start the discussion